HIF1A and hepatocellular carcinoma: Chen and coworkers demonstrated that RNAi against HIF-1α could improve the efficacy of TAE and reduce undesirable effects in the treatment of HCC by TAE through suppressing VEGF and the microvessel density (MVD).